OvaCure Project Portfolio
Each of OvaCure’s projects is conducted by world-leading experts within the fields of immunotherapy, oncology and gynaecology and is guided by OvaCure’s Scientific and Clinical Advisory Board.
Only ground-breaking projects are selected
In collaboration with the Anticancer Fund and the OvaCure Scientific and the Clinical Advisory Board, OvaCure has generated a project portfolio of two Danish and three international projects. Each project developed through OvaCure has maximum potential for the development of curative treatments for ovarian cancer patients.
OvaCure Initiated Projects
T-cell infusion Project (DK)
Original title: “Immunotherapy by adoptive T-cell infusion in the event of advanced ovarian cancer (stage III and IV) and treatment trials for a total of 18 women”.
The project is conducted at the Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Copenhagen, Denmark. Principal investigator: Head of OvaCure Immunotherapy Dream Collaboration, Professor Inge Marie Svane, MD, PhD.
T-cell combination therapy Project (NL)
Original title: “Combined chemo and adoptive T-cell therapy (ACT) as treatment for recurrent epithelial ovarian carcinoma”.
This project is conducted at the Leiden University Medical Center, Leiden, the Netherlands. Principal investigator: Els M. E. Verdegaal, PhD.
Personal T-Cell Project(CH)
Original title: “Harnessing tumour diversity to develop personalised adoptive immunotherapy for ovarian cancer”.
This pre-clinical project is conducted at the Ludwig Center for Cancer Research, University of Lausanne, Switzerland. Principal investigator: Professor George Coukos, MD, PhD.
Therapeutic Personal Vaccine Project (CH)
Original title: “A Phase I/II study to test the feasibility, safety and immunogenicity of personalized mutanome peptide (PMP) vaccine vs. whole tumor oxidized lysate (OC-L) vaccine admixed with CpG adjuvant, in combination with low-dose cyclophosphamide in primary advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.”
This project is conducted at the Ludwig Center for Cancer Research, University of Lausanne, Switzerland. Principal investigator: Professor George Coukos, MD, PhD.
Tumour-Match Project (DK)
Original title:”Molecular profiling of advanced gynaecological cancers in targeted therapies”.
This project will be conducted at Nordic Society of Gyneacological Oncology at Rigshospitalet, Denmark. Principal investigator: Mirza, Mansoor Raza, MD, Chief Oncologist.
OvaCure Immunotherapy Dream Collaboration
OvaCure’s flagship project (T-cell Infusion) is among the world’s first trials to treat ovarian cancer patients with adoptive T-cell therapy (ACT). The clinical phase I of this project is now almost complete. OvaCure’s 2nd project, T-cell Combination, will be conducted under the same clinical trial protocol and further the investigation by combining ACT with IFNα and chemotherapy. The subsequent projects based in Lausanne will further analyse individual ovarian tumour mutation-specific antigens as well as develop novel personalised vaccination programs.
The OvaCure Immunotherapy Dream Collaboration is planned to enrol approximately 46 women. All projects involved unique, interdependent, in-patient trials offering personalised immunotherapy to women with advanced ovarian cancer.
OvaCure plays an instrumental part in ensuring synergies between the projects and ensuring that the results are disseminated within the scientific community. Projects work in Dream Collaborations and are linked and share protocols and results. This creates a synergy that is not only unique but also acts to fast track the clinical trials process, thus brings treatments, from bench to bed - faster.
CAR T-cell therapy Project (US)
Original title: “CAR T-cell therapy for widespread application in recurrent Epithelial Ovarian Cancer”.
This project will be conducted at the Perelman School of Medicine, the University of Pennsylvania, PA, USA. Principal investigator: Carl June, MD, PhD.